Related Experiment Video
Updated: May 16, 2025
Thermal Ablation for the Treatment of Abdominal Tumors
Published on: March 7, 2011
Percutaneous MR-Guided Thermal Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma
Jin Chen1, Bing Zhang2, Yuan Yan3
1Department of Interventional Radiology, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China (J.C., B.Z., Y.Y., F.-Q.W., R.G., B.-Y.H., Z.-Y.L.); Department of Interventional Radiology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China (J.C., Y.Y., F.-Q.W., R.G., B.-Y.H., Z.-Y.L.); Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China (J.C., Z.-Y.L.).
Rationale And Objectives:
To evaluate the technical efficacy and therapeutic outcomes of percutaneous MR-guided thermal ablation, including microwave ablation (MWA) and radiofrequency ablation (RFA) for recurrent subcentimeter hepatocellular carcinomas (HCCs). MATERIALS AND METHODS: From January 2015 to May 2024, we recruited 101 patients with 119 recurrent subcentimeter HCCs (mean diameter: 8.0±1.3 mm, range: 5.6-9.9mm), who were treated with MR-guided thermal ablation. Technical success, technical efficacy, complications, and local tumor progression (LTP) rate were evaluated after ablation. Cumulative LTP rate, recurrence-free survival (RFS), and overall survival (OS) rates were estimated using the Kaplan-Meier method.
Results:
A retrospective analysis showed that MR-guided thermal ablation (MWA, n=84; RFA, n=17) was successfully executed in all cases. Technical success and efficacy were achieved in all lesions in single sessions without major complications. The mean follow-up duration was 41.1±27.1 months (median:38.0 months; range:3-105 months). The cumulative LTP rate at 1 year was 1.2%, and 5.8% at 3, 5, 7, and 9 years. The cumulative RFS rates at 1, 3, 5, 7, and 9 years were 82.2%, 44.6%, 29.0%, 23.2%, and 23.2%, respectively. The cumulative OS rates at 1, 3, 5, 7, and 9 years were 99.0%, 91.8%, 84.4%, 69.7%, and 62.0%, respectively.
Conclusion:
Percutaneous MR-guided thermal ablation for recurrent subcentimeter HCCs demonstrated ready visualization of lesions and ablation margins as well as high technical efficacy rate, and minimal LTP after a single treatment session.
More Related Videos
04:22Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019